HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression

Ahn,Mee‑Young

doi:10.3892/ol.2018.9468

HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression

Authors:
- Mee‑Young Ahn
View Affiliations

Affiliations: Department of Pharmaceutical Engineering, Division of Bio‑industry, College of Medical and Life Sciences, Silla University, Busan 46958, Republic of Korea
Published online on: September 20, 2018 https://doi.org/10.3892/ol.2018.9468
Pages: 6552-6560
Copyright: © Ahn . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apicidin, a cyclic peptide histone deacetylase (HDAC) inhibitor, has been demonstrated to exhibit antitumor activity in a number of human cancer types. The present study examined the antitumor activity of apicidin in murine oral squamous cell carcinoma (OSCC) cells. Inhibition of cell proliferation and the expression of selective HDACs were determined in apicidin‑treated AT‑84 murine OSCC cells. A C3H mouse model with subcutaneous injection of AT‑84 cells was used to assess the in vivo effect of apicidin on tumor growth. Apicidin‑induced cell growth inhibition and selectively reduced HDAC8 expression in AT‑84 cells. Induction of apoptosis and autophagy was observed in apicidin‑treated AT‑84 cells. Apicidin notably inhibited tumor growth by up to 46% relative to the control group at the end of a 14‑day period in a murine tumor model. The immunohistochemistry results in tumor tissues indicated that apicidin inhibited cell proliferation and induced apoptosis and autophagy in AT‑84 cell‑derived tumor tissues. Overexpression of HDAC8 was observed in the nucleus and cytoplasm in tumor tissues and apicidin significantly inhibited the level of HDAC8 expression, compared with the vehicle group. These results indicated that apicidin inhibited cell proliferation through HDAC8 inhibition in murine OSCC cells in vitro and in vivo. The present study indicated that apicidin may be an effective therapeutic agent for OSCC.

View Figures

View References

1	Manal M, Chandrasekar MJ, Gomathi Priya J and Nanjan MJ: Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg Chem. 67:18–42. 2016. View Article : Google Scholar : PubMed/NCBI
2	Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res. 5:981–989. 2007. View Article : Google Scholar : PubMed/NCBI
3	Iizuka M and Smith MM: Functional consequences of histone modifications. Curr Opin Genet Dev. 13:154–160. 2003. View Article : Google Scholar : PubMed/NCBI
4	Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar : PubMed/NCBI
5	Ahn MY and Yoon JH: Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. Oncol Rep. 37:540–546. 2017. View Article : Google Scholar : PubMed/NCBI
6	Kim HJ and Bae SC: Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 3:166–179. 2011.PubMed/NCBI
7	Batty N, Malouf GG and Issa JP: Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 280:192–200. 2009. View Article : Google Scholar : PubMed/NCBI
8	Grant S and Dai Y: Histone deacetylase inhibitors and rational combination therapies. Adv Cancer Res. 116:199–237. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bauden M, Tassidis H and Ansari D: In vitro cytotoxicity evaluation of HDAC inhibitor Apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment. Toxicol Lett. 236:8–15. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ahn MY, Kang DO, Na YJ, Yoon S, Choi WS, Kang KW, Chung HY, Jung JH, do Min S and Kim HS: Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett. 325:189–199. 2012. View Article : Google Scholar : PubMed/NCBI
11	Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST and Min YH: Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin Cancer Res. 9:5018–5027. 2003.PubMed/NCBI
12	Lai JP, Sandhu DS, Moser CD, Cazanave SC, Oseini AM, Shire AM, Shridhar V, Sanderson SO and Roberts LR: Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol. 50:1112–1121. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zhang J, Lai Z, Huang W, Ling H, Lin M, Tang S, Liu Y and Tao Y: Apicidin inhibited proliferation and invasion and induced apoptosis via mitochondrial pathway in non-small cell lung cancer GLC-82 cells. Anticancer Agents Med Chem. 17:1374–1382. 2017. View Article : Google Scholar : PubMed/NCBI
14	Bauden M, Tassidis H and Ansari D: In vitro cytotoxicity evaluation of HDAC inhibitor Apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment. Toxicol Lett. 236:8–15. 2015. View Article : Google Scholar : PubMed/NCBI
15	Ahn MY, Ahn JW, Kim HS, Lee J and Yoon JH: Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells. Oncol Rep. 33:1899–1907. 2015. View Article : Google Scholar : PubMed/NCBI
16	Keleş E, Lianeri M and Jagodziński PP: Apicidin suppresses transcription of 17β-hydroxysteroid dehydrogenase type 1 in endometrial adenocarcinoma cells. Mol Biol Rep. 38:3355–3360. 2011. View Article : Google Scholar : PubMed/NCBI
17	Markopoulos AK: Current aspects on oral squamous cell carcinoma. Open Dent J. 6:126–130. 2012. View Article : Google Scholar : PubMed/NCBI
18	Cheng YS, Rees T and Wright J: A review of research on salivary biomarkers for oral cancer detection. Clin Transl Med. 3:32014. View Article : Google Scholar : PubMed/NCBI
19	Park JW, Kim CH, Ha YC, Kim MY and Park SM: Count of platelet and mean platelet volume score: Serologic prognostic factor in patients with oral squamous cell carcinoma. J Korean Assoc Oral Maxillofac Surg. 43:305–311. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ahn MY, Ahn SG and Yoon JH: Apicidin, a histone deaceylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells. Oral Oncol. 47:1032–1038. 2011. View Article : Google Scholar : PubMed/NCBI
21	Lou E, Kellman RM, Hutchison R and Shillitoe EJ: Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. Oral Dis. 9:305–312. 2003. View Article : Google Scholar : PubMed/NCBI
22	Schultz-Hector S and Haghayegh S: Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res. 53:1444–1449. 1993.PubMed/NCBI
23	Hier MP, Black MJ, Shenouda G, Sadeghi N and Karp S: A murine model for the immunotherapy of head and neck squamous cell carcinoma. Laryngoscope. 105:1077–1080. 1995. View Article : Google Scholar : PubMed/NCBI
24	Pang S, Kang MK, Kung S, Yu D, Lee A, Poon B, Chen IS, Lindemann B and Park NH: Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin Cancer Res. 7:3567–3573. 2001.PubMed/NCBI
25	Murakami J, Asaumi J, Maki Y, Tsujigiwa H, Kuroda M, Nagai N, Yanagi Y, Inoue T, Kawasaki S, Tanaka N, et al: Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncol. 40:597–603. 2004. View Article : Google Scholar : PubMed/NCBI
26	Chung YL, Lee MY and Pui NN: Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis. 30:1387–1397. 2009. View Article : Google Scholar : PubMed/NCBI
27	Rikiishi H: Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol. 2011:8302602011. View Article : Google Scholar : PubMed/NCBI
28	Balasubramanian S, Verner E and Buggy JJ: Isoform-specific histone deacetylase inhibitors: The next step? Cancer Lett. 280:211–221. 2009. View Article : Google Scholar : PubMed/NCBI
29	Kim SN, Choi HY and Kim YK: Regulation of adipocyte differentiation by histone deacetylase inhibitors. Arch Pharm Res. 32:535–541. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ahn MY and Yoon JH: Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. J Oral Pathol Med. 46:276–283. 2017. View Article : Google Scholar : PubMed/NCBI
31	Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT and Kuo MY: Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 45:610–614. 2009. View Article : Google Scholar : PubMed/NCBI
32	Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T and Tanzawa H: Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 29:117–124. 2006.PubMed/NCBI
33	Eisenberg-Lerner A, Bialik S, Simon HU and Kimchi A: Life and death partners: Apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 16:966–975. 2009. View Article : Google Scholar : PubMed/NCBI
34	Ahn MY, Lee J, Na YJ, Choi WS, Lee BM, Kang KW and Kim HS: Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact. 179:169–177. 2009. View Article : Google Scholar : PubMed/NCBI
35	Alirezaei M, Kemball CC, Flynn CT, Wood MR, Whitton JL and Kiosses WB: Short-term fasting induces profound neuronal autophagy. Autophagy. 6:702–710. 2010. View Article : Google Scholar : PubMed/NCBI
36	Yonekawa T and Thorburn A: Autophagy and cell death. Essays Biochem. 55:105–117. 2013. View Article : Google Scholar : PubMed/NCBI
37	Ahn MY, Chung HY, Choi WS, Lee BM, Yoon S and Kim HS: Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4. Int J Oncol. 36:125–131. 2010.PubMed/NCBI
38	Nair DV and Reddy AG: Mouse models of oral cancer: Challenges and opportunities. Int J Adv Biol Res. 7:203–207. 2017.
39	Muskhelishvili L, Latendresse JR, Kodell RL and Henderson EB: Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67(MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem. 51:1681–1688. 2003. View Article : Google Scholar : PubMed/NCBI
40	Velu P, Vinothkumar V, Babukumar S and Ramachandhiran D: Chemopreventive effect of syringic acid on 7,12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis. Toxicol Mech Methods. 27:631–640. 2017. View Article : Google Scholar : PubMed/NCBI
41	Saraç S, Ayhan A, Hosal AS and Kaya S: Prognostic significance of PCNA expression in laryngeal cancer. Arch Otolaryngol Head Neck Surg. 124:1321–1324. 1998. View Article : Google Scholar : PubMed/NCBI
42	Guo X, Ruan H, Li X, Qin L, Tao Y, Qi X, Gao J, Gan L, Duan S and Shen W: Subcellular localization of class I histone deacetylases in the developing xenopus tectum. Front Cell Neurosci. 9:5102016. View Article : Google Scholar : PubMed/NCBI
43	Li Y, Shin D and Kwon SH: Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 280:775–793. 2013.PubMed/NCBI
44	Yang WM, Tsai SC, Wen YD, Fejer G and Seto E: Functional domains of histone deacetylase-3. J Biol Chem. 277:9447–9454. 2002. View Article : Google Scholar : PubMed/NCBI
45	Grozinger CM and Schreiber SL: Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA. 97:7835–7840. 2000. View Article : Google Scholar : PubMed/NCBI
46	Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M and Tsuneyoshi M: Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 18:769–774. 2007.PubMed/NCBI